11 March 2019 - The NICE has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque psoriasis in final draft guidelines.

Initially NICE rejected Illumetri for not being cost-effective, but a new negotiated price submitted by the company means that it can now be offered as an alternative for patients who are unable to take systemic non-biological treatments.

Read Pharma Times article